Impact of Dexmedetomidine Dosing and Timing on Acute Kidney Injury and Renal Outcomes After Cardiac Surgery: A Meta-Analytic Approach
Annals of Pharmacotherapy · 2025
DOI: 10.1177/10600280241271098 ↗Kurz gefasst
Metaanalyse in der Zeitschrift Annals of Pharmacotherapy, 2025. Verfasst von Hongpei Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology, Peking University International Hospital, Beijing, China. Hauptthemen laut MEDLINE: Dexmedetomidine, Acute Kidney Injury, Cardiac Surgical Procedures, Adrenergic alpha-2 Receptor Agonists. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 39 Literaturangaben.
Abstract (Originalsprache)
Background
Acute kidney injury (AKI) is a common and serious complication following cardiac surgery. Dexmedetomidine, a highly selective α2-adrenergic agonist, has shown potential renoprotective effects, but previous studies have yielded conflicting results.
Objective
This meta-analysis aimed to evaluate the efficacy and safety of dexmedetomidine in preventing AKI and reducing postoperative serum creatinine levels in adult patients undergoing cardiac surgery.
Methods
We comprehensively searched 5 databases for randomized controlled trials comparing dexmedetomidine with control groups in adult cardiac surgery patients. The main outcomes were the incidence of AKI and change in postoperative serum creatinine levels. Meta-analyses were conducted using RevMan 5.4 models, and subgroup analyses were performed based on dexmedetomidine dosing and timing of administration. Continuous outcomes were combined and analyzed using either mean difference (M.D.), while dichotomous outcomes were analyzed using risk ratio (RR) with 95% confidence intervals (CI).
Results
Our study included a total of 14 trials involving 2744 patients. Dexmedetomidine administration significantly reduced the incidence of AKI compared to control groups (RR = 0.54, 95% CI: 0.41-0.70, P < 0.00001). Postoperative serum creatinine levels were also lower with dexmedetomidine (MD = −0.14 mg/dL, 95% CI: −0.28 to −0.001, P =0.04). Subgroup analyses revealed that higher initial doses (>0.5 μg/kg) and administration during intraoperative and postoperative periods were associated with more pronounced renoprotective effects. Dexmedetomidine did not significantly affect mortality but reduced the duration of the length of hospital stay and mechanical ventilation. Conclusions and Relevance: This meta-analysis demonstrates that dexmedetomidine administration, particularly at higher doses and during both intraoperative and postoperative periods, reduces the risk of AKI in adults undergoing cardiac surgery. These findings support the use of dexmedetomidine as a preventive strategy to enhance renal outcomes in this population.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology, Peking University International Hospital, Beijing, China.
ORCID-Profile: Lan Yao
Zitieren
APA
Li, H., Wang, L., Shi, C., Zhou, B., & Yao, L. (2025). Impact of Dexmedetomidine Dosing and Timing on Acute Kidney Injury and Renal Outcomes After Cardiac Surgery: A Meta-Analytic Approach. Annals of Pharmacotherapy. https://doi.org/10.1177/10600280241271098
Vancouver
Li H, Wang L, Shi C, Zhou B, Yao L. Impact of Dexmedetomidine Dosing and Timing on Acute Kidney Injury and Renal Outcomes After Cardiac Surgery: A Meta-Analytic Approach. Annals of Pharmacotherapy. 2025. doi:10.1177/10600280241271098
BibTeX
@article{Li2025,
author = {Li, Hongpei and Wang, Lei and Shi, Chunxia and Zhou, Baolong and Yao, Lan},
title = {Impact of Dexmedetomidine Dosing and Timing on Acute Kidney Injury and Renal Outcomes After Cardiac Surgery: A Meta-Analytic Approach},
journal = {Annals of Pharmacotherapy},
year = {2025},
doi = {10.1177/10600280241271098}
}
EUVIMED